YouTube · H1 2026 · 2026-08-23
HCM · NasdaqGS
HUTCHMED (China) Limited
Drug Manufacturers - Specialty & Generic · Hong Kong
USD 13.67-1.1% daily changeQuote 2026-09-18 · USD
- Market cap (USD)
- US$2.38B
- Trailing P/E
- 136.70x
- Forward P/E
- 52.40x
- Quarterly revenue growth
- 0.2%
- Trailing net margin
- 3.3%
- Indicated dividend yield
- —
Snapshot 2026-09-20 · Latest financial period 2026-06-30 · Yahoo Finance. Quotes may be delayed; reporting periods can differ.
Company background
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
Company websiteQ1 2026
Go beyond the headline.
Comparable businesses
HCM peer comparison
Same business group first, then company size. Preferred market cap: 0.5–2x; extended range: one-third–3x. Outside that range, industry benchmarks are labeled separately and excluded from peer medians.
| Metric | HCMHUTCHMED (China) LimitedSnapshot 2026-09-20Financial period: 2026-06-30 | ALVOAlvotechSnapshot 2026-09-20Financial period: 2026-06-30 | PAHCPhibro Animal Health CorporationSnapshot 2026-09-20Financial period: 2026-06-30 | Peer medianSimilar-size peers only |
|---|---|---|---|---|
| Market capMarket value, converted to USD | US$2.38B | US$2.09B | US$1.40B | US$1.75Bn=2 |
| Forward P/EProvider forward earnings estimate | 52.40x | 25.71x | 8.98x | 17.34xn=2 |
| EV / EBITDAEnterprise value / trailing EBITDA | — | 44.94x | 8.66x | 26.80xn=2 |
| Revenue growthLatest quarter vs prior-year quarter | 0.2% | -38.9% | 4.8% | -17.1%n=2 |
| Operating marginLatest reported quarter | 0.3% | -11.1% | 10.6% | -0.2%n=2 |
| Free cash flow yieldTrailing cash flow / market cap | -0.8% | -5.9% | -1.4% | -3.6%n=2 |
| Net debt / EBITDANet debt / trailing EBITDA | — | 17.28x | 2.91x | 10.10xn=2 |
| Debt / equityTotal debt / positive book equity | 0.07x | — | 2.06x | — |
| Trailing P/ETrailing twelve-month earnings | 136.70x | — | 14.22x | — |
| Price / bookPrice / positive book equity per share | 1.88x | — | 3.64x | — |
| EV / salesEnterprise value / trailing revenue | 2.02x | 6.88x | 1.39x | 4.14xn=2 |
| Earnings growthLatest quarter vs prior-year quarter | -96.5% | — | 24.6% | — |
| Gross marginTrailing twelve months | 13.3% | 60.7% | 33.3% | 47.0%n=2 |
| Net marginTrailing twelve months | 3.3% | -36.3% | 6.6% | -14.9%n=2 |
| Return on equityProvider trailing return; positive equity only | 1.5% | — | 29.7% | — |
| Free cash flow marginTrailing free cash flow / revenue | -3.4% | -24.9% | -1.3% | -13.1%n=2 |
| Dividend yieldIndicated annual dividend / price | — | — | 1.4% | — |
| Earnings payoutProvider trailing dividend payout | 0.0% | 0.0% | 19.8% | 9.9%n=2 |
| Current ratioCurrent assets / current liabilities | 5.64x | 1.65x | 2.96x | 2.30xn=2 |
| BetaProvider historical market sensitivity | 0.45 | 0.22 | 0.47 | 0.34n=2 |
YouTube · H1 2026 · 2026-08-23
Phibro Animal Health Corporation (PAHC)
Similar size · 0.59x market cap
Drug Manufacturers - Specialty & Generic
YouTube · Q4 FY2026 · 2026-08-28
Comparison methodology & limitations
Reviewed operating groups override broad sector classifications. Other companies are matched only within a sufficiently specific provider industry. Business mix, geography and accounting standards can still differ. Market caps are converted to USD using exchange rates captured during the snapshot refresh. Financial ratios that would mix currencies are omitted. Snapshots must be at most 14 days old and no more than seven days apart for automatic selection.
Peer medians require at least two valid similar-size peers for each metric. Negative earnings, nonpositive equity, missing data and irrelevant bank ratios are not presented as attractive valuations. A higher or lower number is not automatically a better investment. Financial statement periods are not calendar-aligned across companies.
Reported performance
Financial trends
Periods are grouped by their ending calendar year or quarter, not identical fiscal calendars. Exact period-end dates appear in tooltips and reported figures. When reporting currencies differ and a recent captured FX rate is available, money and EPS are normalized to USD for comparison. This is not a historical FX restatement. Gaps are not estimated.
Financial statements load separately from the research page.
Source: . Window ends at the latest available reporting period.
Revenue
Reported figures
Financial data & calculation notes
Standalone charts use the stated reporting currency. When a chart comparison spans currencies, money and EPS can be normalized to USD using a recent captured FX snapshot; this is for comparison only, not a historical FX restatement. Stock-based compensation is noncash. Free cash flow is operating cash flow less capital spending, which may include capitalized software. Missing metrics are not estimated or assumed to be zero. Banking and insurance ratios require industry-specific interpretation. Latest restatements may differ from figures in older episodes.
Market context
Valuation & price history
Adjusted closing price
Price history loads separately.
Price figures
Earnings-multiple scenario
Illustrative price = your earnings-per-share assumption × your P/E assumption. This is not a price target or a complete valuation model.
Starting assumptions, when available, use provider forward estimates as of 2026-09-20. Negative earnings require a different valuation method. This calculation omits balance-sheet, dilution and execution risks.
THE RESEARCH RECORD
Research history for HCM
Q1 20262026-06-05
HCM Stock: FRUZAQLA +26% + SAFFRON Readout Q1 2026
Presentation · 2026-06-05 · YouTube